Onxeo S.A.: High-Grade Glioma Relapse in Children: Onxeo Announces the Enrollment of the First Patient in the Phase 1b/2 Clinical Study Conducted by the European ITCC Consortium and Sponsored by Institut Curie

Regulatory News: Onxeo S.A. (Euronext Growth: ALONX, Nasdaq First North1: ONXEO), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage

Related Keywords

Luxembourg ,Paris ,France General ,France ,Copenhagen ,Køavn ,Denmark ,Orsay ,French ,Catherine Goupillon ,Marie Curie ,Marie Dutreix ,Emmanuel Huynh ,Arthur Rouill ,Shefali Agarwal ,Kriibskrank Kanner ,Le Tourneau ,Onxeo Sa Euronext ,Institut Curie ,Company Group ,Nasdaq ,Regulatory News ,Euronext Growth ,Nasdaq First ,High Grade Glioma ,Grade Gliomas ,Chief Executive Officer ,Professor Fran ,European Fight Kids ,Carnot Curie ,Euronext Paris ,First North Growth ,Innovative Therapies ,Kids Cancer ,Nasdaq First North ,Onxeo ,Thigh ,Rade ,Glioma ,Relapse ,Children ,Nnounces ,Enrollment ,First ,Patient ,Hase ,Linical ,Study ,Onducted ,European ,Tcc ,Consortium ,Sponsored ,Institut ,Curie ,